$CHRO
Channel Therapeutics Corp Stock $chro

$chro Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000175392624000976 Filed on May 15, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.467M	$1.585M	$728.5K
YoY Change	101.42%	293.79%	197.1%
% of Gross Profit
Research & Development	$466.6K	$2.294M	$186.1K
YoY Change	150.73%	678.75%	336.85%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.934M	$3.879M	$914.6K
YoY Change	111.46%	456.5%	217.68%
Operating Profit	-$1.934M		-$914.6K
YoY Change	111.46%
Interest Expense	-$628.4K	-$160.3K	-$52.00K
YoY Change	1108.37%	276.38%	130.09%
% of Operating Profit
Other Income/Expense, Net	-$628.3K		-$51.98K
YoY Change	1108.87%
Pretax Income	-$2.562M	-$4.039M	-$966.6K
YoY Change	165.09%	446.13%	211.3%
Income Tax
% Of Pretax Income
Net Earnings	-$2.562M	-$4.039M	-$966.6K
YoY Change	165.09%	446.13%	211.3%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.55		-$0.87
Diluted Earnings Per Share	-$0.55	-$0.70	-$0.17
COMMON SHARES
Basic Shares Outstanding	4.691M shares		1.111M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.770M	$96.39K	$49.00K
YoY Change	7594.35%	75.25%
Cash & Equivalents	$3.800M	$100.0K	$48.61K
Short-Term Investments
Other Short-Term Assets	$261.3K
YoY Change
Inventory
Prepaid Expenses	$220.9K
Receivables
Other Receivables
Total Short-Term Assets	$4.032M	$96.39K	$49.00K
YoY Change	8127.67%	75.26%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$4.032M	$96.39K	$49.00K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$4.032M	$96.39K	$49.00K
YoY Change	8127.67%	75.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.408M	$4.626M	$3.366M
YoY Change	-28.48%	54.26%
Accrued Expenses	$493.9K	$645.9K	$344.0K
YoY Change	43.58%	190.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$1.269M	$739.0K
YoY Change	-100.0%	134.94%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.901M	$6.541M	$4.449M
YoY Change	-34.78%	73.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.901M	$6.541M	$4.449M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.901M	$6.541M	$4.449M
YoY Change	-34.78%	73.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$16.08M	-$13.52M
YoY Change		120.23%
Common Stock	$578.00	$391.00
YoY Change		252.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.130M	-$6.445M	-$4.401M
YoY Change
Total Liabilities & Shareholders Equity	$4.032M	$96.39K	$49.00K
YoY Change	8127.67%	75.26%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023 Q1
OPERATING ACTIVITIES
Net Income	-$2.562M	-$4.039M	-$966.6K
YoY Change	165.09%	446.13%	211.3%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.992M	-$356.8K	-$173.4K
YoY Change	1048.73%	-46.48%	-50.64%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$5.972M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$5.666M	430.5K	166.9K
YoY Change	3294.69%	-21.51%	-52.49%
NET CHANGE
Cash From Operating Activities	-$1.992M	-356.8K	-173.4K
Cash From Investing Activities
Cash From Financing Activities	$5.666M	430.5K	166.9K
Net Change In Cash	$3.674M	73.62K	-6.500K
YoY Change	-56620.58%	-162.23%
FREE CASH FLOW
Cash From Operating Activities	-$1.992M	-$356.8K	-$173.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	chro	Due To Chromocell Corporation DueToChromocellCorporation	5386	usd
CY2024Q1	us-gaap	Bridge Loan BridgeLoan		usd
CY2024Q1	us-gaap	Other Loans Payable OtherLoansPayable		usd
CY2024Q1	us-gaap	Loans Payable LoansPayable		usd
CY2024Q1	chro	Due To Chromocell Corporation DueToChromocellCorporation		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2024Q1	chro	Stock Issued During Period Value Standby Agreement StockIssuedDuringPeriodValueStandbyAgreement		usd
CY2023Q1	chro	Due From Chromocell Corporation DueFromChromocellCorporation		usd
CY2023Q1	chro	Prepaid Prepaid		usd
CY2024Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	chro	Debt Discount From Shares Issued On Extension Of Bridge Loan DebtDiscountFromSharesIssuedOnExtensionOfBridgeLoan		usd
CY2023Q1	chro	Conversion Of Notes ConversionOfNotes		usd
CY2023Q1	chro	Transfer Of Liabilities To Chromocell Corp For Preferred Stock TransferOfLiabilitiesToChromocellCorpForPreferredStock		usd
CY2023Q4	us-gaap	Liabilities Liabilities	6540943	usd
CY2023Q4	chro	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLife	P9Y29D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLife	P8Y9M29D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y9M29D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2024Q1	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedOptionsForfeitedNumberOfShares		shares
CY2024Q1	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Warrants Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWarrantsForfeitedWeightedAverageGrantDateFairValue
CY2024Q1	chro	Weighted Average Period For The Unamortized Stock Compensation WeightedAveragePeriodForTheUnamortizedStockCompensation	P2Y1M9D
CY2023Q4	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber		shares
CY2023Q4	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice
CY2023Q4	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingLife	P9Y29D
CY2024Q1	chro	Share Based Compensation Arrangements By Share Based Payment Award Warrants Grants In Period Weighted Average Remaining Life ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageRemainingLife	P9Y1M27D
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExpirationsInPeriod		shares
CY2024Q1	chro	Share Based Compensation Arrangements By Share Based Payment Award Warrants Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	chro	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised		shares
CY2024Q1	chro	Share Based Compensation Arrangements By Share Based Payment Award Warrants Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingLife	P8Y9M29D
CY2024Q1	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1	P8Y9M29D
CY2023Q4	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber		shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2024Q1	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Warrants Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWarrantsForfeitedNumberOfShares		shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2024Q1	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedNumberOfShares		shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2024Q1	us-gaap	Assets Current AssetsCurrent	4031559	usd
CY2024Q1	us-gaap	Assets Assets	4031559	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2407515	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	493924	usd
CY2023Q4	us-gaap	Bridge Loan BridgeLoan	316324	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2901439	usd
CY2024Q1	us-gaap	Liabilities Liabilities	2901439	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5766704	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5766704	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3914338	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3914338	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	578	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17211521	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16081979	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	1130120	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4031559	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	787561	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	477630	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	466606	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	186117	usd
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	679815	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	250836	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	1933982	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	914583	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1933982	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-914583	usd
CY2024Q1	chro	Interest Expense On Promissory Note Related Party InterestExpenseOnPromissoryNoteRelatedParty	628348	usd
CY2023Q1	chro	Interest Expense On Promissory Note Related Party InterestExpenseOnPromissoryNoteRelatedParty	51978	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-628348	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-51978	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2562330	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-966561	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2562330	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-966561	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4690989	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1111112	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3706537	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	272221	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-966561	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4440877	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6444552	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	292552	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	447779	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	5972000	usd
CY2024Q1	chro	Stock Issued During Period Value Recission Of Common Stock StockIssuedDuringPeriodValueRecissionOfCommonStock	-91512	usd
CY2024Q1	chro	Stock Issued During Period Value Transfer Of Liabilities To Chromocell Corp.For Preferred C Shares StockIssuedDuringPeriodValueTransferOfLiabilitiesToChromocellCorp.ForPreferredCShares	2153363	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1362821	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2562330	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	1130120	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2562330	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-966561	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	605630	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	31650	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	292552	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	272221	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	90994	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	367326	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-152023	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	121995	usd
CY2024Q1	chro	Due From Chromocell Corporation DueFromChromocellCorporation	-45786	usd
CY2024Q1	chro	Prepaid Prepaid	-220930	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1991893	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-173369	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	166903	usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-214757	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5972000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	91512	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5665731	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	166903	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3673838	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6466	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96391	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55074	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3770229	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48608	usd
CY2024Q1	chro	Debt Discount From Shares Issued On Extension Of Bridge Loan DebtDiscountFromSharesIssuedOnExtensionOfBridgeLoan	447779	usd
CY2024Q1	chro	Conversion Of Notes ConversionOfNotes	1362821	usd
CY2024Q1	chro	Transfer Of Liabilities To Chromocell Corp For Preferred Stock TransferOfLiabilitiesToChromocellCorpForPreferredStock	2153362	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_806_eus-gaap--NatureOfOperations_zNdFUcfqcao2" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 1 – <span id="xdx_82A_zw2kZgVh2oGi">ORGANIZATION AND NATURE OF BUSINESS</span></b></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Company Background </i></b></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Chromocell Therapeutics Corporation (“Chromocell” or the “Company”) was incorporated in the State of Delaware on March 19, 2021. On August 10, 2022, the Company entered into that certain Contribution Agreement (the “Contribution Agreement”) with Chromocell Corporation, a Delaware corporation (“Chromocell Holdings”), pursuant to which, effective July 12, 2022 (the “Contribution Date”), Chromocell Holdings contributed all assets and liabilities related to Chromocell Holdings’ historical therapeutic business, including all patents, pre-clinical and Phase I study results and data, and trade secrets related to the CC8464 compound to the Company. (See Note 4)</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. The Company’s clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, which has been genetically validated as a pain receptor in human physiology. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”). The Company’s goal is to develop a novel and proprietary class of NaV blockers that target the body’s peripheral nervous system.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has formally launched two programs developing pain treatment therapeutics, both based on the same proprietary molecule, as follows:</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Neuropathic Pain</span>: CC8464 is being developed to address certain types of neuropathic pain. The chemical characteristics of CC8464 restrict its entry into the CNS and limit its effect to the NaV1.7 receptors in the peripheral nervous system, which consists of the nerves outside the brain and spinal cord. Activation of other receptors in the CNS can result in side effects, including addiction and other centrally mediated adverse effects. Since CC8464 is designed to not penetrate the CNS it is highly unlikely to produce CNS mediated side effects including euphoria or addiction. Based on its characteristics, preclinical studies (described below) and the Phase 1 studies the Company has completed to date, the Company believes that CC8464, if approved, could become an attractive option for both patients and physicians as a treatment for moderate-to-severe pain in EM and iSFN.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Eye Pain</span>: Based on the same proprietary molecule as CC8464, the Company’s newly launched program, titled CT2000, is for the potential treatment of both acute and chronic eye pain. NaV1.7 receptor is present on the cornea, making it a viable biological target for treating eye pain. Eye pain may occur with various conditions, including severe dry eye disease, trauma and surgery. Existing therapies for eye pain (such as steroids, topical non-steroidal anti-inflammatory agents, lubricants, local anesthetics) are limited in their effectiveness and/or limited in the duration that they may be prescribed because of safety issues. The Company intends to explore the viability of developing CT2000 as a topical agent for the relief of eye pain. A potential advantage of this approach is that topical administration of CT2000 is unlikely to lead to any hypersensitivity or skin reactions, like what was noted with systemic administration of CC8464, because the systemic absorption from a topical administration would be extremely limited. The Company has commenced development of a topical ophthalmic formulation of CT2000 that would initially be evaluated for ophthalmic toxicology and then followed by a POC trial in patients. The Company expects the trials for this ophthalmic formulation of CT2000 to start in 2025.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may further expand its pipeline with other internal or external compounds in the future, but all other internally discovered compounds are pre-clinical and no commercial discussions about in-licensing have been initiated to date, other than as disclosed in this quarterly report with respect to the licensing of the certain spray formulations from Benuvia Operations LLC (“Benuvia”), entered into on December 23, 2023.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company has a limited operating history and has not generated revenue from its intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include changes in the biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On February 21, 2024, the Company completed the initial public offering of its Common Stock (the “IPO”) and issued 1,100,000 shares of its Common Stock at a price of $6.00 per share. The aggregate net proceeds from the IPO were approximately $5.7 million after deducting underwriting discounts and commissions and offering expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2562330	usd
CY2024Q1	us-gaap	Cash Cash	3770229	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3800000	usd
CY2024Q1	chro	Working Capital Deficit WorkingCapitalDeficit	1100000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100000	usd
CY2023Q4	chro	Working Capital Deficit WorkingCapitalDeficit	6400000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zB8rzLmSf3C5" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i><span id="xdx_86A_zlyx33YhRmO4">Use of Estimates</span></i></b></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, realization of long-lived assets, valuation of deferred income taxes, unrealized tax positions and business combination accounting.</span></p>
CY2024Q1	chro	Disaggregation Of R And D Expenses DisaggregationOfRAndDExpenses	<p id="xdx_895_ecustom--DisaggregationOfRAndDExpenses_z4I1wPx22YYg" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B1_z63thajasuLe">Below is a disaggregation of R&D expenses:</span></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Consultant</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__srt--ProductOrServiceAxis__custom--ConsultantMember_zz7G3LtfFzSd" style="width: 12%; text-align: right" title="Research and development expense">30,033</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__srt--ProductOrServiceAxis__custom--ConsultantMember_zMGq0MAOYzHi" style="width: 12%; text-align: right" title="Research and development expense">16,400</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab Gas</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__srt--ProductOrServiceAxis__custom--LabGasMember_zRaqjyeeVGh9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__srt--ProductOrServiceAxis__custom--LabGasMember_zgskk2ATAzc6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lab Cell Storage</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__srt--ProductOrServiceAxis__custom--LabCellStorageMember_zkqCKSV9SSFa" style="text-align: right">24,127</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__srt--ProductOrServiceAxis__custom--LabCellStorageMember_zgJHMrvG3RVa" style="text-align: right">10,100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Chemistry Manufacturing and Controls (“CMC”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__srt--ProductOrServiceAxis__custom--ChemistryManufacturingAndControlsMember_zTTqRPMUGIv1" style="text-align: right">303,397</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__srt--ProductOrServiceAxis__custom--ChemistryManufacturingAndControlsMember_zc99SOa9MLKg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0474">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">IP Services</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__srt--ProductOrServiceAxis__custom--IPServicesMember_zHRadsFNnKQ" style="border-bottom: Black 1pt solid; text-align: right">109,049</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__srt--ProductOrServiceAxis__custom--IPServicesMember_zaSfXJiXsps9" style="border-bottom: Black 1pt solid; text-align: right">159,617</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331_zsT0iPROG2M" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense">466,606</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_zUvGMCiz0X01" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense">186,117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	466606	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	186117	usd
CY2022Q4	chro	Director Note Description DirectorNoteDescription	the Company and Mr. Todd Davis, one of the Company’s directors, entered into the Director Note for $175,000. The Director Note has an original issuance discount of $75,000, and matures on December 31, 2023, or, if earlier to occur, upon the closing of an underwritten offering of securities resulting in at least $15 million in gross proceeds. On December 28, 2023, the Company entered into an amendment to the Director Note, which extended the maturity date to February 29, 2024. On February 21, 2024, the principal and accrued interest on this note converted into 29,167 shares of the Company’s Common Stock.
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	75000	usd
CY2022Q4	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	15000000	usd
CY2024Q1	chro	Due To Receivable DueToReceivable	40400	usd
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	450000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	150000	usd
CY2022Q1	us-gaap	Investment Interest Rate InvestmentInterestRate	0.50	pure
CY2022Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-02-03
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	14370	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	135630	usd
CY2023Q1	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	the Investor Note agreement was amended. The maturity date was extended from its original due date of February 3, 2023 to May 15, 2023, in return for the Company agreeing to pay 2% per month in accrued interest and the third party agreeing to settle its outstanding debt, including accrued interests in shares of Common Stock at the IPO. Accrued interest and related interest expense totaled $15,517 for the three months ended March 31, 2024, compared to $17,036 for year ended March 31, 2023.
CY2023Q2	us-gaap	Debt Conversion Description DebtConversionDescription	(ii) in consideration therefor, issued to such holder 50,000 shares of Common Stock. The Company determined that this extension qualified as a modification of the Investor Note rather than an extinguishment. The Company recorded an expense of $126,000 from the issuance of the 556 shares of Common Stock based on a share price of $22.68. The $22.68 share price was based on a third-party valuation of the Company’s Common Stock, with certain adjustments as set forth below in detail in Note 7 – Stockholders’ Equity.
CY2023Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	1203704	shares
CY2024Q1	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	(ii) in consideration therefor, the Company would issue upon close of the IPO, and regardless of whether the Company would have issued any shares of Series B Preferred Stock, an aggregate of 4,167 shares (such shares, the “Standby Shares”) of Common Stock to the Standby Investor (such agreement, the “Series B Securities Purchase Agreement”). In addition, pursuant to the Series B Securities Purchase Agreement, the Company was required to file a registration statement within 180 calendar days after consummation of the IPO, providing for the resale of the Standby Shares and shares of Common Stock issuable upon conversion of the Series B Preferred Stock, if issued.
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44800000	usd
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1187302	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	37.71
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44800000	usd
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1187302	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	37.71
CY2022Q3	chro	Illiquidity Discount IlliquidityDiscount	20	pure
CY2022Q3	chro	Minority Discount MinorityDiscount	20	pure
CY2022Q3	chro	Fair Value Of Common Stock Per Share FairValueOfCommonStockPerShare	22.68
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	197560	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	197560	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	127723	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.68
CY2023Q4	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedNumberOfShares	113429	shares
CY2023Q4	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedWeightedAverageGrantDateFairValue	22.68
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	43592	shares
CY2024Q1	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsVestedWeightedAverageGrantDateFairValue	22.68
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	69837	shares
CY2024Q1	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonvestedWeightedAverageGrantDateFairValue	22.68
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	106669	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	22.68
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2024Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	292552	usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	272221	usd
CY2024Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1561727	usd
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriodGross	55000	shares
CY2024Q1	chro	Share Based Compensation Arrangements By Share Based Payment Award Warrants Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice	7.50
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber	55000	shares
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice	7.50
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber	55000	shares
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice	7.50
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriodGross	55000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.50
CY2024Q1	chro	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsVestedNumberOfShares	55000	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	7.50
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriod	55000	shares
CY2023Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriod	0	shares
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriodGrantDateIntrinsicValue	7.50
CY2024Q1	chro	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Expense Or Revenue Recognized ClassOfWarrantOrRightExpenseOrRevenueRecognized	the Company issued warrants to purchase up to 55,000 shares of Common Stock to the representative of the underwriters of the IPO (the “Representative”). These warrants have an exercise price of $7.50, have a cashless exercise provision, are exercisable 180 days following the commencement of sales of the shares of Common Stock of the IPO and have an expiration date of February 21, 2029.
CY2024Q1	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	479169	usd
CY2024Q1	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	479169	usd
CY2024Q1	us-gaap	Other Expenses OtherExpenses	363091	usd
CY2024Q2	us-gaap	Loss Contingency Allegations LossContingencyAllegations	pay an initial lump-sum payment of $10,000 toward outstanding rent and provide a copy of its Registration Statement on Form S-1 for the Company’s IPO (the “Registration Statement”) and (iii) make a final one-time lump sum payment to the EDA of $510,701 to satisfy Chromocell Holdings’ outstanding rent and additional rent obligations within 90 days of Chromocell Holdings’ executing the Settlement Agreement or within 15 days of Chromocell Holdings’ IPO, whichever was the first to occur. The complaint alleges Chromocell Holdings’ breach of each of these provisions of the Settlement Agreement and seeks a judgment for the entire amount allegedly due and owing as of September 12, 2023 ($510,701), compensatory damages, pre-judgment interest, attorney’s fees, costs of suit and such other and further relief as the court deems just and proper.

Files In Submission

Name	View Source	Status
0001753926-24-000976-index-headers.html	Edgar Link	pending
0001753926-24-000976-index.html	Edgar Link	pending
0001753926-24-000976.txt	Edgar Link	pending
0001753926-24-000976-xbrl.zip	Edgar Link	pending
chro-20240331.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g084223_10q.htm	Edgar Link	pending
g084223_ex10-1.htm	Edgar Link	pending
g084223_ex10-2.htm	Edgar Link	pending
g084223_ex10-3.htm	Edgar Link	pending
g084223_ex31-1.htm	Edgar Link	pending
g084223_ex32-1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
chro-20240331_def.xml	Edgar Link	unprocessable
chro-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
g084223_10q_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
chro-20240331_cal.xml	Edgar Link	unprocessable
chro-20240331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CHRO
Channel Therapeutics Corp Stock $chro

2024 Q1 Form 10-Q Financial Statement

#000175392624000976 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRO Channel Therapeutics Corp Stock $chro

2024 Q1 Form 10-Q Financial Statement

#000175392624000976 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRO
Channel Therapeutics Corp Stock $chro